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Introduction
Calcium release activated calcium channels inhibitors
have a potent role in treatment of autoimmune disor-
ders mediated dysregulated T-lymphocyte and mast cell
functioning. Herein, we describe the pre-clinical of
RP3133, a novel and potent CRAC channel inhibitor
with scope for development as a clinical candidate for
asthma.
Methods
Inhibition of CRAC channel activity in Jurkat cells, cyto-
kine release from human whole blood or PBMC, and
mast cell degranulation were estimated. In vivo efficacy
of the compound was determined in experimental mod-
els of asthma in guinea pigs including PAF or ovalbu-
min induced eosinophil infiltration into lungs ovalbumin
induced histamine release from mast cells, and airway
hyper-responsiveness.
Results
RP3133 significantly inhibited calcium entry into Jurkat
cells (38 nM) besides reducing IL-4 (<550 nM) and IL-
5 (<750 nM) release from human whole blood and
PBMC. Additionally, the compound suppressed IgE-
induced mast cell degranulation at nanomolar concen-
trations (139 nM). Oral administration of RP3133 in gui-
nea pigs resulted in a dramatic reduction in eosinophil
infiltration in an acute model of PAF-induced allergic
asthma (ED50 = 0.2 mg/kg/p.o) as well as in an experi-
mental model of ovalbumin-induced chronic airway
inflammation (ED50 = 2.5 mg/kg/p.o). Additionally,
RP3133 caused a significant reduction (P<0.05) citric
acid, histamine, or methacholine induced airway resis-
tance in sensitized guinea pigs. Consistent with in vitro
findings, the compound caused a significant inhibition of
mast cell degranulation manifested by a reduction in his-
tamine release.
Conclusions
Results demonstrate the potential of RP3133 as an anti-
asthmatic agent as evidenced from pre-clinical data.
Toxicological evaluation of the molecule is currently in
progress.
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